You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Under the agreement, Bioneer will supply instruments, nucleic acid extraction reagents, and COVID-19 test kits, which will be placed at medical institutions in Qatar.
The South Korean company has now received CE marking for its hepatitis B, hepatitis C, and HIV-1 detection kits, which run on its ExiStation system.
The test is the second infectious disease assay from Bioneer to be CE marked, and the South Korean company has a third test in the pipeline.
The assay, which uses the Bioneer ExiStation molecular diagnostics instrument, was also recently registered for purchase by the Global Fund.
The kit is designed to quantify HIV-1 RNA in blood samples and runs on Bioneer's PCR-based ExiStation automated molecular diagnostics system.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.